Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay
Mental Retardation, Developmental Delay Disorder
About this trial
This is an interventional treatment trial for Mental Retardation focused on measuring Severe aberrant behavior, Risperidone, Clozapine, Haloperidol, Laboratory operant tasks, Simple acquisition procedures, Matching to sample task, Lag sequential analysis
Eligibility Criteria
Inclusion Criteria Primary diagnosis of mental retardation (IQ < 70) Scheduled for medication reductions from psychotropic drugs and subsequent placement on risperidone Severe self-injury, aggression, property destruction, or stereotypic behavior for 6 months prior to study entry No seizures, or seizures under control of medication for previous 2 years Additional Inclusion Criteria for Substudy Participants in the primary study who are available for 2 hour weekly or bi-weekly clinic visits and are able to have observers in their home, school, and/or work environment Exclusion Criteria Degenerative disease that may affect motor or cognitive functioning Progressive disease of an organ system Advanced age that may produce deteriorating cognitive or motor functioning Multiple sensory or motor disabilities that will interfere with seeing the stimuli and responding to the computer
Sites / Locations
- University of Kansas